BrainStorm Cell Therapeutics Inc. is a biotechnology company developing autologous adult stem cell therapies for neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and Parkinson's disease (PD).

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-10-29)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BrainStorm Cell Therapeutics I (BCLI US)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-10-29)

Current Report (Form 8-K | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-10-01)

Current Report (Form 8-K | Period ending 2024-09-26)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)